Switch theme
Sign up to access all valuation multiples
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
2015
3
Last FY Revenue n/a
Last FY EBITDA -$1.8M
$11.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, NLS Pharmaceutics achieved revenue of n/a and an EBITDA of -$1.8M.
NLS Pharmaceutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NLS Pharmaceutics valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$1.8M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | -$3.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | -$2.0M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, NLS Pharmaceutics's stock price is $2.
NLS Pharmaceutics has current market cap of $9.9M, and EV of $11.1M.
See NLS Pharmaceutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.1M | $9.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, NLS Pharmaceutics has market cap of $9.9M and EV of $11.1M.
NLS Pharmaceutics's trades at n/a EV/Revenue multiple, and -6.1x EV/EBITDA.
Equity research analysts estimate NLS Pharmaceutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NLS Pharmaceutics's P/E ratio is not available.
See valuation multiples for NLS Pharmaceutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.9M | XXX | $9.9M | XXX | XXX | XXX |
| EV (current) | $11.1M | XXX | $11.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -6.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -3.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -5.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNLS Pharmaceutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.
NLS Pharmaceutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NLS Pharmaceutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for NLS Pharmaceutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NLS Pharmaceutics acquired XXX companies to date.
Last acquisition by NLS Pharmaceutics was XXXXXXXX, XXXXX XXXXX XXXXXX . NLS Pharmaceutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was NLS Pharmaceutics founded? | NLS Pharmaceutics was founded in 2015. |
| Where is NLS Pharmaceutics headquartered? | NLS Pharmaceutics is headquartered in United States of America. |
| How many employees does NLS Pharmaceutics have? | As of today, NLS Pharmaceutics has 3 employees. |
| Who is the CEO of NLS Pharmaceutics? | NLS Pharmaceutics's CEO is Mr. Alexander Zwyer. |
| Is NLS Pharmaceutics publicy listed? | Yes, NLS Pharmaceutics is a public company listed on NAS. |
| What is the stock symbol of NLS Pharmaceutics? | NLS Pharmaceutics trades under NLSP ticker. |
| When did NLS Pharmaceutics go public? | NLS Pharmaceutics went public in 2021. |
| Who are competitors of NLS Pharmaceutics? | Similar companies to NLS Pharmaceutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of NLS Pharmaceutics? | NLS Pharmaceutics's current market cap is $9.9M |
| Is NLS Pharmaceutics profitable? | Yes, NLS Pharmaceutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
